Frontlight ResearchEarly access
CompletedPhase 3
A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
Key facts
- Who runs it
- Ionis Pharmaceuticals, Inc.
- Where
- Ann Arbor, Birmingham, Boca Raton, Brooklyn, Cedar Park, Charlotte, Chattanooga, Chicago, Chiefland, Chula Vista, Columbus, Council Bluffs, Dallas, Flint, Great Neck, Greensboro, Houston, Huntington Beach, Jacksonville, Kansas City, La Jolla, Las Vegas, Lincoln, Los Angeles, Manassas, Medford, Miami, Middletown, Miramar, Monroe, Morgantown, Mount Airy, Munroe Falls, New York, Niagara Falls, Norfolk, Oak Brook, Ocala, Oklahoma City, Providence, Rapid City, Salem, Scottsdale, St Louis, St. Petersburg, Sugar Land, Syosset, Tampa, Tarzana, Towson, Trinity, Union City, and West Jordan, United StatesSee the 56 sitesAlso in 22 other countries, 153 sites
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 617 people enrolled
- Started
- 25 Oct 2021
- Ended
- 8 Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Olezarsen
- Placebo
- Record updated
- 10 February 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification
- Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study
Who cannot take part
- Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening
- Total bilirubin > upper limit of normal unless due to Gilbert's syndrome
- Estimated GFR < 30 mL/min/1.73 m\^2
- Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal
Where in United States
Also in 22 other countries, 153 sites
- University of Michigan Hospital and Health Systems/ Dept. of Pharmacy-Research PharmacyAnn Arbor, United States
- Accel Research Sites NetworkBirmingham, United States
- Excel Medical Clinical Trials, LLCBoca Raton, United States
- Modern MedicineBrooklyn, United States
- Velocity Clinical ResearchCedar Park, United States
- Novant Health Cancer Institute Elizabeth Investigational Drug ServicesCharlotte, United States
- Chattanooga Research & Medicine, PLLCChattanooga, United States
- IMA Clinical Research ChicagoChicago, United States
- Southeast Clinical Research LLCChiefland, United States
- Velocity Clinical ResearchChula Vista, United States
- Aventiv ResearchColumbus, United States
- IACT HealthColumbus, United States
- West Broadway ClinicCouncil Bluffs, United States
- University of Texas, SouthwesternDallas, United States
- Aa Mrc LlcFlint, United States
- Northwell HealthGreat Neck, United States
- Cone Medical CenterGreensboro, United States
- Baylor College of MedicineHouston, United States
- Diabetes/Lipid Management & Research CenterHuntington Beach, United States
- Westside Center for Clinical ResearchJacksonville, United States
- Kansas University Medical CenterKansas City, United States
- University of California San Diego (UCSD)La Jolla, United States
- Palm Research Center IncLas Vegas, United States
- Bryan Medical Center Clinical ResearchLincoln, United States
- LA Universal Research Center, Inc.Los Angeles, United States
- Manassas Clinical Research CenterManassas, United States
- Velocity Clinical ResearchMedford, United States
- Finlay Medical ResearchMiami, United States
- Circuit Clinical (Crystal Run Healthcare)Middletown, United States
- Innovia Research Center, Inc.Miramar, United States
- Clinical Trials of America, LLCMonroe, United States
- West Virginia University Heart and Vascular InstituteMorgantown, United States
- Clinical Trials of America, LLCMount Airy, United States
- Summit Research Group LLCMunroe Falls, United States
- Columbia UniversityNew York, United States
- NYU LangoneNew York, United States
- Circuit ClinicalNiagara Falls, United States
- York Clinical Research LLCNorfolk, United States
- Affinity HealthOak Brook, United States
- Ocala Cardiovascular ResearchOcala, United States
- Hightower Clinical Trial ServicesOklahoma City, United States
- The Miriam HospitalProvidence, United States
- Health ConceptsRapid City, United States
- Wake Forest University Health SciencesSalem, United States
- Mayo ClinicScottsdale, United States
- IMA Clinical ResearchSt Louis, United States
- Washington University School of MedicineSt Louis, United States
- IMA Clinical ResearchSt. Petersburg, United States
- Medicus Alliance Clinical ResearchSugar Land, United States
- Modern MedicalSyosset, United States
- Vicis Clinical ResearchTampa, United States
- America Clinical TrialsTarzana, United States
- Continental Clinical SolutionsTowson, United States
- Bayside Clinical ResearchTrinity, United States
- Hudson County Clinical Trials Research CenterUnion City, United States
- Velocity ClinicalWest Jordan, United States
About the trial
What the trial wants to find out
The purpose of the study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
The 2 groups in the trial
- OlezarsenTreatment being tested
Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
- PlaceboPlacebo, for comparison
Olezarsen-matching placebo will be administered once every 4 weeks by SC injection from Week 1 through Week 49.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
- Publications
- Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.The New England journal of medicine, 2026
- Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia.American heart journal, 2025
- Record updated
- 10 February 2026